Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07339787
Recruiting Observational

Diagnosis of Transient Ischemic Attacks in the Emergency Department

NCT07339787 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2025-02-06
Last updated
2026-01-14

Condition(s) studied

Transient Ischemic AttackCardiovascular Morbidity

Study summary

Patients presenting a Transient Ischemic Attack (TIA) and admitted to the Emergency Department should be referred to a neurovascular specialist. In recent years, several hospitals have established TIA clinics. These units are day hospitals where all the necessary examinations are performed. Access to this expertise has proven beneficial in reducing cardiovascular morbidity and mortality, particularly the risk of early recurrence. Unfortunately, this access is limited by issues of medical demographics and unequal access to the healthcare system. In practice, this ideal care is not always possible. A portion of the TIA population is at low risk, and diagnostic and therapeutic interventions are limited, not always requiring neurovascular expertise.

The hypothesis of this research is that the management of a patient who has suffered a TIA (additional examinations, treatment, referral) is not linked to their cardiovascular risk and that the performance of additional examinations and therapies is incomplete.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult (≥18 years old) * Having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory) * TIA will be defined as a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department Exclusion Criteria: \- Subjects with a suspected diagnosis of TIA, i.e., with a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department.

Primary outcome measure(s)

  • ABCD2 Score — Up to 12 months
    The ABCD2 score is a medical tool used by doctors after a TIA (Transient Ischemic Attack). The total score ranges from 0 to 7: * 0-3: low risk * 4-5: moderate risk * 6-7: high risk

Trial sites (1)

FacilityCityRegionStatus
Service d'Urgences Médico-Chirurgicales Adules - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers Active, not recruiting
Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease Recruiting
Impact of Perioperative Organ Resuscitation of Brain-dead Deceased Organ Donor on Kidney Graft Function in the Recipient Recruiting
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025 Recruiting

Other trials for the same condition

Smartwatch-Guided Secondary Prevention After Stroke Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07339787 on ClinicalTrials.gov ↗ ← All trials in France